State Street
CMMB

State Street’s Chemomab Therapeutics CMMB Stock Holding History

State Street’s Portfolio CMMB Stock Details CMMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-7,160
Closed -$71K – 4869
2022
Q3 		$71K Sell
7,160
-1,886
-21% -$24.3K ﹤0.01% 4572
2022
Q2 		$134K Buy
9,046
+194
+2% +$2.7K ﹤0.01% 4380
2022
Q1 		$171K Buy
8,852
+680
+8% +$13.4K ﹤0.01% 4439
2021
Q4 		$226K Buy
8,172
+546
+7% +$19.4K ﹤0.01% 4293
2021
Q3 		$338K Buy
+7,626
New +$464K ﹤0.01% 4131

Other funds holding CMMB

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
KPWS
Kestra Private Wealth Services Austin, Texas $8.11B AUM 24.74% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ASN
Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street's CMMB Position: Q4 2022 in Review

State Street sold out of Chemomab Therapeutics (CMMB) in Q4 2022, closing a stake of 7,160 shares — an estimated $71K sold.

State Street first reported a position in CMMB in Q3 2021 and held it in 5 quarters. The position peaked at $338K in Q3 2021. 14 funds tracked by Wall St. Rank hold CMMB as of Q4 2022.

  • State Street reported no remaining Chemomab Therapeutics position as of Q4 2022 after selling out during the quarter.
  • State Street sold 7,160 Chemomab Therapeutics shares in Q4 2022, an estimated $71K.
  • State Street first reported a position in Chemomab Therapeutics in Q3 2021 and held it in 5 quarters.
  • State Street's Chemomab Therapeutics position peaked at $338K in Q3 2021.
  • 14 funds tracked by Wall St. Rank held Chemomab Therapeutics as of Q4 2022.

Based on State Street's 13F filing for Q4 2022, filed 14 Feb 2023.